Fortress Biotech Inc (FBIO) FinancialsFBIOFortress Biotech Inc

Fortress Biotech Inc (FBIO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Journey, accounting for 98.9% of total sales, equivalent to $18.51M. Another important revenue stream is Fortress. Understanding this composition is critical for investors evaluating how FBIO navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Fortress Biotech Inc maintains a gross margin of 62.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -53.46%, while the net margin is 3.22%. These profitability ratios, combined with a Return on Equity (ROE) of 99.36%, provide a clear picture of how effectively FBIO converts its operational activities into shareholder value.

In the context of the broader market, FBIO competes directly with industry leaders such as ATRA and PTHS. With a market capitalization of $97.72M, it holds a leading position in the sector. When comparing efficiency, FBIO's gross margin of 62.00% stands against ATRA's 69.68% and PTHS's 70.18%. Such benchmarking helps identify whether Fortress Biotech Inc is trading at a premium or discount relative to its financial performance.

Fortress Biotech's revenue has shown growth, with Q2 2026 revenue at $18.72 million, up from $16.04 million in Q1 2026. However, net income remains volatile, with a recent net income of -$2.48 million in Q2 2026.